Peter Wehrwein, Managing Editor

Witty was the top executive of the country's largest healthcare company during some of its darkest chapters, including the killing of the head of its health insurance business.

The survey was conducted from March 10 through April 9, when the Department of Government Efficiency was in news

High costs and the novelty and complexity of new therapies such as gene therapy present social determinants of health and health literacy challenges, says Tiara Green, president of Accessia Health

Cost is a barrier to care for chronic and rare diseases, so financial assistance is way to lower that barrier and help people manage their health condition, says Green, president of Accessia Health

Payers and providers, often depicted as rivals, are on the same side when it comes to the 340B program that allows some hospitals to buy drugs at steep discounts, according to Milliman experts.

The actor expressed some regret as well as gratitude in talking about the death of his 33-year-old son from a rare form of sarcoma.

Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.

The margins are small, and the services they provide must be “high touch.” 340B participation and cost-plus pricing are floated as tactics the pharmacies might use to improve their economics.

The vice president and lead of IQVIA's Market Access Center of Excellence says fewer drugs are hitting the $100 million mark during their first year on the market than in the past.

The vice president and market lead of IQVIA's Market Center of Excellence gives some insight intot the title of his talk today at Asembia meeting.

McElya, senior director, clinical pharmacy at Walgreens, notes that approximately half of the drugs approved by the FDA last year were first-in-class drugs.

Researchers in Taiwan find no difference in fungal disease among patients treated with two different types of GVHD prophylaxis.

Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for short-bowel syndrome.

On lobbying, hospitals, PBM reform and 340B

On lobbying, the political power of hospitals, PBM reform and 340B

Republicans are aiming for major reductions in federal spending, and Medicaid seems a likely target. But the politics of Medicaid are tricky as the program has expanded and covered more people.

In this second part of a video series, Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, described a common scenario where patients with severe atopic dermatitis must first try and fail multiple topical treatments, all while having widespread symptoms, before insurers will approve systemic therapies.

CMS announced today that Medicare Advantages would increase by 5.06% in 2026.

In a recent Managed Healthcare Executive K-Cast video series, R. Robert Auger, M.D., a psychiatrist and sleep specialist at the Mayo Clinic in Rochester, Minnesota, spoke about the diagnosis and treatment of narcolepsy and idiopathic hypersomnia. This is a written recap of that series.

By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with chronic kidney disease as those without it, and there are signals that it has benefits for renal function.

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) narrowed in the FAME 3 five-year follow-up study, but there were fewer myocardial infarctions and repeat revascularizations in the PCI group.

In this second part of his interview with Managed Healthcare Executive, John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, discusses lifestyle management and GLP-1s.

John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 per month would make the GLP-1s cost-effective as a prevention measure.